MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: Efficacy and tolerability in specific patient subpopulations

Alimentary Pharmacology and Therapeutics

Volumn 27, Issue 11, 2008, Pages 1094-1102

  Lichtenstein, G R ^a,g   Kamm, M A ^b,c   Sandborn, W J ^d   Lyne, A ^e   Joseph, R E ^f  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b ST VINCENT S HOSPITAL   (Australia)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d MAYO CLINIC   (United States)

^e Shire Pharmaceuticals   (United Kingdom)

^f SHIRE   (United States)

^g HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE; MEXAVANT XL; MEZAVANT; MULTI MATRIX SYSTEM; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; COLONOSCOPY; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GENDER; HUMAN; LOW DRUG DOSE; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REMISSION; ULCERATIVE COLITIS;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MESALAMINE; MIDDLE AGED; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX;

EID: 42949096844     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03688.x     Document Type: Article

References (13)

1. Kornbluth A, Sachar DB. Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004 99 : 1371 85.
2. Prantera C, Viscido A, Biancone L, Francavilla A, Giglio L, Campieri M. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis 2005 11 : 421 7.
3. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007 132 : 66 75.
4. Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007 5 : 95 102.
5. Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987 92 : 1894 8.
6. ®) mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Alim Pharmacol Ther 2007 26 : 205 15.
7. De Vos M, Verdievel H, Schoonjans R, Praet M, Bogaert M, Barbier F. Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations. Gut 1992 33 : 1338 42.
8. Frieri G, Pimpo MT, Palumbo GC, et al. Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment. Aliment Pharmacol Ther 1999 13 : 1413 7.
9. Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005 54 : 960 5.
10. Loftus EV Jr. A practical perspective on ulcerative colitis: patients' needs from aminosalicylate therapies. Inflamm Bowel Dis 2006 12 : 1107 13.
11. Hanauer S, Sandborn W, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005 100 : 2478 85.
12. Höie O, Wolters F, Riis L, et al. European Collaborative Study Group of Inflammatory Bowel Disease (EC-IBD). Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. Am J Gastroenterol 2007 105 : 1692 701.
13. Karban A, Eliakim R. Effect of smoking on inflammatory bowel disease: Is it disease or organ specific? World J Gastroenterol 2007 13 : 2150 2.